Hematologic Malignancy
Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
CI-CAN-00005967PTCLExplore in graph →
Hematologic172 active trials13 approved drugs9 evidence items
Loading cancer entity…
Hematologic Malignancy
CI-CAN-00005967PTCLExplore in graph →
Clinical trials
786 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (129)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07842445 | Phase 1a/1b Clinical Trials to Evaluate the Safety and Preliminary Efficacy of GNTbm-38. | not yet recruiting | Phase 1 | 70 | Great Novel Therapeutics Biotech & Medicals CorporationINDUSTRY | 0 | Sep 25, 2026 | clinicaltrials |
| NCT04301076 | Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATLL) | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 23, 2026 |
| clinicaltrials |
| NCT05627245 | Testing the Safety of the Anti-cancer Drugs Tazemetostat and Belinostat in Patients With Lymphomas That Have Resisted Treatment | active not recruiting | Phase 1 | 48 | National Cancer Institute (NCI)NIH | 1 | Sep 18, 2026 | clinicaltrials |
| NCT05944562 | Tulmimetostat (DZR123) in Patients With Mycosis Fungoides and Sézary Syndrome | active not recruiting | Phase 1 | 24 | Washington University School of MedicineOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05949944 | Linperlisib in Combination With CHOP in Previously Untreated Peripheral T-Cell Lymphoma | active not recruiting | Phase 1 / Phase 2 | 44 | Sun Yat-sen UniversityOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06137144 | AZD3470 as Monotherapy or in Combination With Anticancer Agent(s) in Participants With Haematologic Malignancies.(PRIMAVERA) | recruiting | Phase 1 / Phase 2 | 161 | AstraZenecaINDUSTRY | 11 | Sep 14, 2026 | clinicaltrials |
| NCT05589896 | A First-in-Human Study of HLA-Partially to Fully Matched Allogenic Cryopreserved Deceased Donor Bone Marrow Transplantation for Patients With Hematologic Malignancies | active not recruiting | Phase 1 / Phase 2 | 12 | Ossium Health, Inc.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT06393738 | A Study of ARV-393 in Relapsed/Refractory Non-Hodgkin Lymphoma. | recruiting | Phase 1 | 329 | Arvinas Inc.INDUSTRY | 5 | Sep 4, 2026 | clinicaltrials |
| NCT07758491 | A Phase I/II Study of FG-M131 in TRBC1+ Relapsed/Refractory Peripheral T-Cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 110 | FutureGen Biopharmaceutical (Beijing) Co., LtdINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT06495723 | Polyspecific Antibodies in Lymphoproliferative T-cell Disorders(PALT1) | recruiting | Phase 1 / Phase 2 | 54 | Xenothera SASINDUSTRY | 2 | Aug 20, 2026 | clinicaltrials |
| NCT00336063 | Vorinostat and Azacitidine in Treating Patients With Locally Recurrent or Metastatic Nasopharyngeal Cancer or Nasal Natural Killer T-Cell Lymphoma | active not recruiting | Phase 1 | 18 | National Cancer Institute (NCI)NIH | 4 | Aug 19, 2026 | clinicaltrials |
| NCT07754890 | Golidocitinib and Chidamide for Cutaneous T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 65 | Peking Union Medical College HospitalOTHER | 1 | Aug 12, 2026 | clinicaltrials |
| NCT03011814 | Durvalumab With or Without Lenalidomide in Treating Patients With Relapsed or Refractory Cutaneous or Peripheral T Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 78 | City of Hope Medical CenterOTHER | 1 | Jul 31, 2026 | clinicaltrials |
| NCT04652960 | Duvelisib and Nivolumab for the Treatment of Stage IIB-IVB Mycosis Fungoides and Sezary Syndrome | active not recruiting | Phase 1 | 38 | National Cancer Institute (NCI)NIH | 1 | Jul 31, 2026 | clinicaltrials |
| NCT07730515 | Clinical Study of XNW5004 Combined With CHOP/CHOEP in the Treatment of Untreated Peripheral T-Cell Lymphoma | recruiting | Phase 1 / Phase 2 | 176 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jul 29, 2026 | clinicaltrials |
| NCT07729397 | Autologous IC-Nine, CD30 CAR, and Constitutive IL7R Expressing EBVST for CD30 Lymphoma (ANCILE-30)(ANCILE-30) | not yet recruiting | Phase 1 | 21 | The Methodist Hospital Research InstituteOTHER | 1 | Jul 27, 2026 | clinicaltrials |
| NCT07724782 | Multi-Cohort Study of Zeprumetostat Combinations for Relapsed/Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 33 | Tianjin Medical University Cancer Institute and HospitalOTHER | 1 | Jul 24, 2026 | clinicaltrials |
| NCT07725705 | SHR2554 Plus Liposomal Mitoxantrone as First-line Treatment for Peripheral T-cell Lymphoma (PTCL) | not yet recruiting | Phase 1 / Phase 2 | 44 | Institute of Hematology & Blood Diseases Hospital, ChinaOTHER | 0 | Jul 24, 2026 | clinicaltrials |
| NCT06176690 | Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas(CABAL2) | recruiting | Phase 1 | 90 | Baylor College of MedicineOTHER | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07714187 | A Study of Topical Duvelisib in Participants With Early-stage Mycosis Fungoides | not yet recruiting | Phase 1 | 30 | SecuraBioINDUSTRY | 1 | Jul 20, 2026 | clinicaltrials |
| NCT07706959 | New Genotype-guided Treatment in Newly Diagnosed PTCL(G08) | not yet recruiting | Phase 1 / Phase 2 | 108 | Ruijin HospitalOTHER | 1 | Jul 16, 2026 | clinicaltrials |
| NCT07691450 | Belinostat in Combination With Azacitidine or Pralatrexate for the Treatment of Relapse or Refractory T-cell Lymphoma | not yet recruiting | Phase 1 | 40 | City of Hope Medical CenterOTHER | 1 | Jul 9, 2026 | clinicaltrials |
| NCT06508463 | Intravenous Vesicular Stomatitis Virus in Patients With Peripheral T-cell Lymphoma | recruiting | Phase 1 | 21 | Mayo ClinicOTHER | 1 | Jul 1, 2026 | clinicaltrials |
| NCT02520791 | Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma | active not recruiting | Phase 1 | 21 | National Cancer Institute (NCI)NIH | 2 | Jun 26, 2026 | clinicaltrials |
| NCT04068597 | Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies | recruiting | Phase 1 / Phase 2 | 250 | CellCentric Ltd.INDUSTRY | 5 | Jun 24, 2026 | clinicaltrials |
| NCT07502768 | Tislelizumab Plus Zeprumetostat for Relapsed or Refractory NK/T-Cell Lymphoma(EpiRev-NKT) | recruiting | Phase 1 / Phase 2 | 107 | Rong TaoOTHER | 1 | Jun 18, 2026 | clinicaltrials |
| NCT05475925 | A Study of DR-01 in Subjects With Large Granular Lymphocytic Leukemia or Cytotoxic Lymphomas | recruiting | Phase 1 / Phase 2 | 200 | Dren BioINDUSTRY | 9 | Jun 17, 2026 | clinicaltrials |
| NCT03602157 | Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL | active not recruiting | Phase 1 | 43 | UNC Lineberger Comprehensive Cancer CenterOTHER | 1 | Jun 12, 2026 | clinicaltrials |
| NCT07278856 | Ruxolitinib in Combination With CHOP Chemotherapy for the Treatment of Untreated Nodal T-Follicular Helper Cell Lymphomas | recruiting | Phase 1 | 20 | City of Hope Medical CenterOTHER | 1 | Jun 5, 2026 | clinicaltrials |
| NCT03598998 | Pembrolizumab and Pralatrexate in Treating Patients With Relapsed or Refractory Peripheral T-Cell Lymphomas | active not recruiting | Phase 1 / Phase 2 | 13 | City of Hope Medical CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT07001384 | A Study of Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL) | recruiting | Phase 1 | 30 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 26, 2026 | clinicaltrials |
| NCT02797470 | Gene Therapy in Treating Patients With Human Immunodeficiency Virus-Related Lymphoma Receiving Stem Cell Transplant | active not recruiting | Phase 1 / Phase 2 | 11 | AIDS Malignancy ConsortiumNETWORK | 1 | May 18, 2026 | clinicaltrials |
| NCT06874946 | Nanobody-Based Anti-CD5 CAR-T for Relapsed/Refractory T-ALL/NHL(Phase I/II) | recruiting | Phase 1 / Phase 2 | 30 | Peking University People's HospitalOTHER | 1 | May 7, 2026 | clinicaltrials |
| NCT07075328 | A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma | recruiting | Phase 1 / Phase 2 | 49 | Otsuka Medical Devices Co., Ltd. JapanINDUSTRY | 1 | Apr 29, 2026 | clinicaltrials |
| NCT07535710 | Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-cell Lymphoma | not yet recruiting | Phase 1 / Phase 2 | 37 | Shanghai Jiao Tong University School of MedicineOTHER | 1 | Apr 17, 2026 | clinicaltrials |
| NCT07523555 | Adaptive Dual-Target CAR-T Cells for Relapsed or Refractory Hematologic Malignancies(ADAPT-HEM) | recruiting | Phase 1 / Phase 2 | 96 | Beijing BiotechINDUSTRY | 1 | Apr 13, 2026 | clinicaltrials |
| NCT07525466 | Combination of Mitoxantrone Liposome and Etoposide, Dexamethasone, Pegaspargase and Golidocitinib (MEPL-G) in the Treatment of NK/T-cell Lymphoma Associated Hemophagocytic Lymphohistiocytosis (NKTCL-HLH) | recruiting | Phase 1 / Phase 2 | 25 | Beijing Tongren HospitalOTHER | 1 | Apr 13, 2026 | clinicaltrials |
| NCT03240211 | Study of Pembrolizumab Combined With Decitabine and Pralatrexate in PTCL and CTCL | active not recruiting | Phase 1 | 37 | University of VirginiaOTHER | 1 | Apr 7, 2026 | clinicaltrials |
| NCT07493330 | Genotype-guided Targeted Agents Plus EZH2i for Primary Refractory PTCL | not yet recruiting | Phase 1 / Phase 2 | 86 | Ruijin HospitalOTHER | 0 | Apr 7, 2026 | clinicaltrials |
| NCT05544968 | Anti-CD30 biAb-AATC in Patients With Relapsed/Refractory CD30 Positive Hematopoietic Malignancies | recruiting | Phase 1 | 42 | Medical College of WisconsinOTHER | 1 | Apr 3, 2026 | clinicaltrials |
| NCT07047885 | Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL) | recruiting | Phase 1 | 38 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Apr 1, 2026 | clinicaltrials |
| NCT07018752 | A Platform Trial Evaluating New Drugs or Combination in R/R Peripheral T-cell Lymphomas(PlaTform) | recruiting | Phase 1 / Phase 2 | 49 | The Lymphoma Academic Research OrganisationOTHER | 1 | Feb 11, 2026 | clinicaltrials |
| NCT04848064 | Third-Party Natural Killer Cells and Mogamulizumab for the Treatment of Relapsed or Refractory Cutaneous T-cell Lymphomas or Adult T-Cell Leukemia/Lymphoma | recruiting | Phase 1 | 12 | John ReneauOTHER | 1 | Feb 10, 2026 | clinicaltrials |
| NCT05296304 | A Study of Bexarotene Combined With Radiotherapy in People With Mycosis Fungoides | recruiting | Phase 1 | 20 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Feb 4, 2026 | clinicaltrials |
| NCT04390737 | Evaluate the Safety and Clinical Activity of HH2853 | recruiting | Phase 1 / Phase 2 | 254 | Haihe Biopharma Co., Ltd.INDUSTRY | 2 | Jan 30, 2026 | clinicaltrials |
| NCT07339527 | EZH2 Inhibitor Zeprumetostat in Combination Therapy for Patients With Relapsed or Refractory Mature T-cell and NK-cell Lymphomas | not yet recruiting | Phase 1 / Phase 2 | 60 | Sun Yat-sen UniversityOTHER | 0 | Jan 14, 2026 | clinicaltrials |
| NCT03278782 | Study of Pembrolizumab (MK-3475) in Combination With Romidepsin | active not recruiting | Phase 1 / Phase 2 | 39 | M.D. Anderson Cancer CenterOTHER | 1 | Jan 9, 2026 | clinicaltrials |
| NCT04686682 | A First-in-Human, JAB-8263 in Adult Patients With Advanced Tumors | recruiting | Phase 1 / Phase 2 | 152 | Jacobio Pharmaceuticals Co., Ltd.INDUSTRY | 1 | Jan 9, 2026 | clinicaltrials |
Data updated 4 days agoSource updated Sep 25, 2026source: clinicaltrials